Wells Fargo & Company Uro Gen Pharma Ltd. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$43.4 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$42.8 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$26.4 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$25.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$25 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $260M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...